TARS · NASDAQ · Biotechnology

Tarsus Pharmaceuticals (TARS)

Commercializes XDEMVY for Demodex blepharitis and develops additional eye-care and infectious-disease therapies.

$75.58
vs last close−1.50 (−1.94%)